

Prior Authorization DRUG Guidelines

lotilaner (Xdemvy)

Date Developed: 03/25/2025

Date Approved by P&T Committee: 04/17/2025

OVERVIEW

XDEMZY is an ectoparasiticide (anti-parasitic) that treats Demodex blepharitis. It inhibits the gamma-aminobutyric acid (GABA)-gated chloride channels of Demodex mites resulting in paralysis and subsequent death.

The following condition(s) require Prior Authorization:

Demodex blepharitis

NOTE: Must be prescribed by or in consultation with an ophthalmologist or optometrist.

DOSAGE AND ADMINISTRATION

XDEMZY (lotilaner ophthalmic solution) 0.25% (2.5 mg/mL) is a topical ophthalmic drop that is taken twice daily (approximately 12 hours apart) for six weeks. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart. If one dose is missed, treatment should continue with the next scheduled dose.

NOTE: Contact lenses should be removed prior to instillation of XDEMZY and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS

The most common adverse reaction was instillation site stinging and burning

CONTRAINDICATIONS

None

REFERENCES

Drug Trials Snapshots: XDEMZY. U.S. Food & Drug Administration (FDA), (2024, October 11).
<https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xdemzy>

UpToDate. (2025). Lotilaner: Drug Information
<https://www.uptodate.com/contents/lotilaner-drug-information>

XDEMZY Drug Packet Insertion. Prescribing Information. U.S. Food & Drug Administration (FDA), Tarsus Pharmaceuticals, Inc. Irvine, CA 92618. (2023, July).
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217603s000lbl.pdf

Review History:

Policy created by Howard Taekman, MD/Dr. Robert Sterling on 03/25/2025

Date Reviewed/Updated: 3/25/25 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 04/17/2025

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes